STOCK TITAN

Ionis Pharmaceuticals (NASDAQ: IONS) Rule 144 notice for 5,619 RSU shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Ionis Pharmaceuticals files a Rule 144 notice to sell 5,619 shares of Common Stock. The filing lists the securities as RSUs granted under the 2011 Equity Incentive Plan with an intended sale date of 04/16/2026. The notice also reports prior open-market sales of 4,096, 5,296, and 6,907 shares on 03/03/2026, 01/30/2026, and 01/16/2026, respectively.

Positive

  • None.

Negative

  • None.
Registered/offered shares 5,619 shares Rule 144 notice dated 04/16/2026
Prior sale on 03/03/2026 4,096 shares Executed through Stifel Nicolaus & Company Inc
Prior sale on 01/30/2026 5,296 shares Executed through Morgan Stanley Smith Barney
Prior sale on 01/16/2026 6,907 shares Executed through Morgan Stanley Smith Barney
Gross proceeds example $325,059.00 Gross proceeds reported for 4,096-share sale on 03/03/2026
Gross proceeds example $439,693.50 Gross proceeds reported for 5,296-share sale on 01/30/2026
Gross proceeds example $523,205.25 Gross proceeds reported for 6,907-share sale on 01/16/2026
Rule 144 regulatory
"Rule 144 notice to sell 5,619 shares of Common Stock"
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
RSU financial
"RSUs granted under the 2011 Equity Incentive Plan"
Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.
2011 Equity Incentive Plan financial
"RSUs granted under the 2011 Equity Incentive Plan"

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Ionis Pharmaceuticals' Form 144 for IONS report?

It reports a proposed sale of 5,619 shares of Common Stock as a Rule 144 notice. The shares are described as RSUs under the 2011 Equity Incentive Plan, with an intended sale date of 04/16/2026.

Who appears as broker/dealer on the IONS Form 144 filing?

The filing lists Morgan Stanley Smith Barney (1585 Broadway, New York) and Stifel Nicolaus & Company Inc as brokers. Broker names are provided alongside the reported sale dates and share amounts.

What recent share sales does the IONS filing disclose?

It discloses prior sales of 4,096 shares on 03/03/2026, 5,296 shares on 01/30/2026, and 6,907 shares on 01/16/2026. Each sale is shown with the executing broker and gross proceeds.

Are the shares in the IONS Form 144 from compensation awards?

Yes. The filing specifies the securities as RSUs granted under the 2011 Equity Incentive Plan, indicating the shares originate from compensation-related awards rather than an underwritten offering.